Shareprice
27 May 2024

Press & news

FluoGuide develops surgical solutions that are expected to reduce suffering for the patient and increase the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

2023

29 November, 2023 FluoGuide A/S publishes interim report for the period January – September 2023 News English Regulatory Listing Regulation Report Interim Q3 IR
Copenhagen, Denmark, 29 November 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its...
13 November, 2023 FluoGuide announces FG001 meets primary endpoint in phase llb trial in aggressive brain cancer News Corporate Action Other English Regulatory MAR IR
Copenhagen, Denmark – FluoGuide A/S (“FluoGuide” or the “Company”), a pioneer in the cutting-edge field...
Copenhagen, Denmark – FluoGuide A/S (“FluoGuide” or the “Company”), a pioneer in the cutting-edge field...
3 October, 2023 FluoGuide receives FDA Orphan Drug Designation for FG001 in high-grade glioma News Corporate Action Other English Regulatory MAR IR
Copenhagen, Denmark – FluoGuide A/S (OMX: FLUO “FluoGuide” or the “Company”), a pioneer in the cutting-edge...
8 September, 2023 FluoGuide receives Danish award for the best share price performance since IPO News Corporate Action Other English IR
Copenhagen, Denmark, 8 September 2023 – FluoGuide A/S (“FluoGuide” or the “Company”), a pioneer in the...
Copenhagen, Denmark, 7 September 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to see...
30 August, 2023 FluoGuide A/S publishes interim report for the period January – June 2023 News English Regulatory Listing Regulation Report Interim Q2 IR
Copenhagen, Denmark, 30 August 2023 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its...
29 August, 2023 FluoGuide reports further positive interim data from phase IIa trial of FG001 in head & neck cancer News Corporate Action Other English Regulatory MAR IR
Copenhagen, Denmark – FluoGuide A/S (“FluoGuide” or the “Company”), a pioneer in the cutting-edge field...
28 August, 2023 FluoGuide completes patient enrollment and treatment in FG001 phase llb clinical trial in aggressive brain cancer News Corporate Information Other Corporate Information English IR
Copenhagen, Denmark – FluoGuide A/S (“FluoGuide” or the “Company”), a pioneer in the cutting-edge field...

Calendar &
upcoming reports


8-10 January 2024

SEB Nordic Seminar


28 February 2024

Økonomisk Ugebrev Life Science Investor Conference


28 February 2024

Year end report 2023

Show all posts